| Administration of Subcutaneous Medications in Palliative Care using a NIPRO Surefuser™
|
SESLHDPR/666 |
|
| Administration of subcutaneous medications in Palliative Care: a) Intermittent b) Via a syringe driver
|
SESLHDPR/175 |
|
Advance Care Planning
|
SESLHDGL/077 |
|
| Assessment and Documentation to Verify Death - Palliative Care Community Nurses
|
SESLHDPR/492 |
|
| Cancer Services – Use of eviQ Cancer Treatments Online
|
SESLHDPD/276 |
|
| Clinical Pathway Guideline
|
SESLHDGL/037 |
|
| COVID-19 - End of Life Symptom Management
|
SESLHDGL/101 |
|
| Dealing with family conflict in end-of-life decision making - checklist for senior medical staff
|
SESLHDGL/091 |
|
| Management of the Deteriorating ADULT inpatient (excluding maternity)
|
SESLHDPR/697 |
|
| Palliative Care: administration of Adult Subcutaneous fluid
|
SESLHDPR/422 |
|
| Referral to Palliative Care
|
SESLHDGL/100 |
|
| Sickle Cell Crisis - Management of Patients Presenting in Sickle Cell Crisis
|
SESLHDPR/609 |
|
| Subcutaneous Needle Insertion and Management
|
SESLHDPR/19 |
|
| Subcutaneous phenobarbital for refractory terminal agitation and uncontrolled seizures (including status epilepticus) in the imminently dying patient
|
SESLHDPR/695 |
|
| Terminal Care / End of Life Plan
|
SESLHDPD/308 |
|
| Wound - Incontinence Associated Dermatitis (IAD)
|
SESLHDPR/205 |
|
